MRK vs NVO Stock Comparison: AI Score, Valuation, Performance and Upside
Merck is generally evaluated as a diversified pharmaceutical company managing the eventual patent cliff of its blockbuster oncology drug Keytruda while building out its next wave of growth drivers, while Novo Nordisk is assessed almost entirely through the lens of its GLP-1 franchise and its competitive position against Eli Lilly in obesity and diabetes care. Both are large, established pharmaceutical companies but face very different concentration risks. The choice depends on whether an investor prefers diversified oncology and vaccine exposure or concentrated GLP-1 growth exposure.
Merck suits investors wanting diversified pharmaceutical exposure with a defined patent-cliff risk to underwrite, while Novo Nordisk offers more concentrated growth exposure to the GLP-1 obesity and diabetes market alongside intensifying competitive pressure.
NVO holds the edge across 3 of 5 key metrics in this comparison. MRK has delivered stronger 1-year price return (+72.62% vs -27.40%), though NVO has the better forward P/E setup (1.71x vs 15.55x for MRK). On fundamentals, MRK is growing revenue faster (5.10%), while NVO maintains the higher operating margin (42.54%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for NVO (+17.00%) than for MRK (+0.26%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want diversified exposure across oncology, vaccines, and animal health
- Are comfortable underwriting the eventual Keytruda patent cliff
- Believe in Merck's pipeline and business development strategy to replace future revenue
- Value a well-established dividend-paying pharmaceutical company
- Want concentrated exposure to the GLP-1 obesity and diabetes drug market
- Believe Novo Nordisk can defend share against Eli Lilly's competing drugs
- Value continued manufacturing capacity expansion supporting future growth
- Are comfortable with European pharma valuation and reporting conventions
| Metric | MRK | NVO |
|---|---|---|
| AI scorei | 51.3 | 40.8 |
| AI ranki | #424 | #1088 |
| Latest closei | $145.19 | $39.22 |
| 1M returni | +0.97% | -7.78% |
| 3M returni | +13.76% | -22.84% |
| 6M returni | +25.75% | -2.95% |
| 1Y returni | +72.62% | -27.40% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | MRK | NVO |
|---|---|---|
| 1Y ago | $17.3K (+73.0%) started 2025-10-16 | $7.62K (-23.8%) started 2025-10-15 |
| 5Y ago | $23.29K (+132.9%) started 2021-10-18 | $9.68K (-3.2%) started 2021-10-15 |
| 10Y ago | $42.76K (+327.6%) started 2016-10-17 | $31.84K (+218.4%) started 2016-10-17 |
Hypothetical — past performance does not guarantee future results.
| Metric | MRK | NVO |
|---|---|---|
| Market capi | $366B | $173.08B |
| Trailing P/Ei | 118.68 | 9.59 |
| Forward P/Ei | 15.55 | 1.71 |
| Price/Salesi | 3.10 | 0.53 |
| EV/Revenuei | 6.20 | 0.82 |
| Analyst targeti | $148.73 | $45.89 |
| Target upsidei | +0.26% | +17.00% |
| Metric | MRK | NVO |
|---|---|---|
| Revenue growthi | 5.10% | 2.10% |
| Earnings growthi | -19.30% | -20.60% |
| EPS growthi | -19.30% | -20.60% |
| FCF margini | +22.79% | +11.44% |
| Operating margini | -0.24% | 42.54% |
| Profit margini | 4.77% | 35.35% |
| ROIC proxyi | 6.96% | 59.81% |
| Return on equityi | 6.96% | 59.81% |
| Dividend yieldi | 2.29% | 4.58% |
| Payout ratioi | 266.67% | 43.10% |
| Dividend growth streaki | No increase yet | 7 yrs |
| Betai | 0.21 | 0.38 |
| Debt/equityi | 128.41 | 63.33 |
| Current ratioi | 1.32 | 0.87 |
| Quick ratioi | 0.74 | 0.64 |
Over the past year, MRK and NVO have moved barely in the same direction (correlation of 0.09), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | MRK | NVO |
|---|---|---|---|
| 1Y | Growthi | +73.01% | -27.40% |
| CAGRi | +73.17% | -27.42% | |
| Volatilityi | 29.42% | 45.65% | |
| Sharpe ratioi | 1.86 | -0.57 | |
| Sortino ratioi | 3.32 | -0.75 | |
| Max drawdowni | 11.90% | 43.67% | |
| Current drawdowni | 7.20% | 35.64% | |
| Avg drawdowni | 3.72% | 23.92% | |
| Ulcer Indexi | 4.87% | 26.63% | |
| Max daily dropi | 4.06% | 16.43% | |
| Max wkly dropi | 6.49% | 26.95% | |
| 5Y | Growthi | +108.86% | -14.05% |
| CAGRi | +15.89% | -2.98% | |
| Volatilityi | 24.79% | 39.04% | |
| Sharpe ratioi | 0.54 | 0.01 | |
| Sortino ratioi | 0.79 | 0.01 | |
| Max drawdowni | 43.44% | 74.70% | |
| Current drawdowni | 7.20% | 71.09% | |
| Avg drawdowni | 12.63% | 26.51% | |
| Ulcer Indexi | 17.30% | 37.60% | |
| Max daily dropi | 9.86% | 21.83% | |
| Max wkly dropi | 13.42% | 33.45% | |
| 10Y | Growthi | +219.68% | +145.67% |
| CAGRi | +12.33% | +9.41% | |
| Volatilityi | 23.41% | 32.79% | |
| Sharpe ratioi | 0.42 | 0.30 | |
| Sortino ratioi | 0.61 | 0.42 | |
| Max drawdowni | 43.44% | 74.70% | |
| Current drawdowni | 7.20% | 71.09% | |
| Avg drawdowni | 9.84% | 17.30% | |
| Ulcer Indexi | 13.74% | 27.62% | |
| Max daily dropi | 9.86% | 21.83% | |
| Max wkly dropi | 13.71% | 33.45% |
| Category | MRK | NVO |
|---|---|---|
| Company | Merck & Co., Inc. | Novo Nordisk A/S |
| Sector | Healthcare | Healthcare / Pharmaceuticals |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Core business | Merck develops and markets pharmaceuticals and vaccines, with its oncology drug Keytruda representing a large share of revenue alongside a broader diversified portfolio. | Novo Nordisk is a Danish pharmaceutical company and maker of semaglutide-based drugs Ozempic and Wegovy, alongside a broader diabetes and rare-disease portfolio. |
| Investor focus | Investors watch the timeline for Keytruda's patent expiration and its subcutaneous reformulation strategy, pipeline diversification progress, and vaccine and animal health segment performance. | Investors focus on GLP-1 market share retention against Eli Lilly, manufacturing capacity expansion, and pricing pressure in the U.S. obesity-drug market. |
- Keytruda remains one of the best-selling oncology drugs globally with continued indication expansion
- Diversified portfolio spanning oncology, vaccines, and animal health
- Active business development strategy to diversify revenue ahead of patent cliffs
- Global leadership in GLP-1 diabetes and obesity treatments
- Large manufacturing capacity expansion underway to meet Wegovy demand
- Diversified pipeline beyond GLP-1, including rare disease and cardiovascular drugs
- Looming loss of exclusivity on Keytruda represents a significant revenue cliff risk later in the decade
- Pipeline must successfully replace revenue from maturing blockbuster drugs
- Vaccine segment faces demand normalization after pandemic-era highs
- Intensifying competition from Eli Lilly's tirzepatide franchise
- Pricing pressure and channel disruption from compounded and telehealth-distributed alternatives
- Execution risk on manufacturing scale-up and new formulation rollouts
Compare more than two at a time
This page is a fixed writeup on MRK and NVO. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside MRK and NVO, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.